Altimmune (ALT) Times Interest Earned (2010 - 2026)
Altimmune (ALT) posted quarterly Times Interest Earned of -$9.04 for Q1 2026, down 3.68% year-over-year from -$9.38 in Q1 2025, and up 64.35% quarter-over-quarter from -$25.34 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Times Interest Earned (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Times Interest Earned for 17 consecutive years, with -$9.04 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 3.68% year-over-year to -$9.04; the TTM figure through Mar 2026 stood at -$36.12 (up 7.92% YoY), while the FY2025 annual figure was -$32.57, down 3259.75% from the prior year.
- Times Interest Earned advanced to -$9.04 in Q1 2026 per ALT's latest filing, from -$25.34 in the prior quarter.
- Across five years, Times Interest Earned topped out at $126.2 in Q4 2022 and bottomed at -$24866.0 in Q4 2024.
- Historically, Times Interest Earned has averaged -$2521.6 across 5 years, with a median of -$24.8 in 2023.
- On a YoY basis, Times Interest Earned climbed as much as 107.83% in 2022 and fell as far as 21748.56% in 2022.
- Altimmune's Times Interest Earned stood at $126.2 in 2022, then plunged by 13421.66% to -$16811.5 in 2023, then slumped by 47.91% to -$24866.0 in 2024, then jumped by 99.9% to -$25.34 in 2025, then surged by 64.35% to -$9.04 in 2026.
- Business Quant data shows ALT's Times Interest Earned at -$9.04 in Q1 2026, -$25.34 in Q4 2025, and -$13.98 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 1.42 |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.08 |
| 10 | Altimmune | 625.13 Mn | 625.13 Mn | - | -23.91 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.91 |
| Mar 31, 2026 | -22.70 |
| Dec 31, 2025 | -32.98 |
| Sep 30, 2025 | -42.14 |
| Jun 30, 2025 | -86.83 |
| Mar 31, 2025 | -21,815.00 |
| Dec 31, 2024 | -24,866.00 |
| Sep 30, 2024 | -4,127.83 |
| Jun 30, 2024 | -26,745.00 |
| Mar 31, 2024 | -26,794.00 |
| Dec 31, 2023 | -16,811.50 |
| Sep 30, 2023 | -777.24 |
| Jun 30, 2023 | -9,003.50 |
| Mar 31, 2023 | -10,879.50 |
| Dec 31, 2022 | 126.20 |
| Sep 30, 2022 | -386.75 |
| Jun 30, 2022 | -313.77 |
| Mar 31, 2022 | -314.50 |
| Dec 31, 2021 | 386.85 |
| Sep 30, 2021 | -1,006.18 |